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Abstract
Patient-reported outcome measures (PROMs), tools to assess patient self-report of health status, are now
increasingly used in research, care and policymaking. While there are two well-developed disease-specific
PROMs for interstitial lung diseases (ILD) and idiopathic pulmonary fibrosis (IPF), many unmet and
urgent needs remain. In December 2019, 64 international ILD experts convened in Erice, Italy to deliberate
on many topics, including PROMs in ILD. This review summarises the history of PROMs in ILD,
shortcomings of the existing tools, challenges of development, validation and implementation of their use
in clinical trials, and the discussion held during the meeting. Development of disease-specific PROMs for
ILD including IPF with robust methodology and validation in concordance with guidance from regulatory
authorities have increased user confidence in PROMs. Minimal clinically important difference for
bidirectional changes may need to be developed. Cross-cultural validation and linguistic adaptations are
necessary in addition to robust psychometric properties for effective PROM use in multinational clinical
trials. PROM burden of use should be reduced through appropriate use of digital technologies and
computerised adaptive testing. Active patient engagement in all stages from development, testing, choosing
and implementation of PROMs can help improve probability of success and further growth.
Introduction
Patient-reported outcomes (PROs) have become increasingly important in medicine and in the field of
interstitial lung diseases (ILDs) including idiopathic pulmonary fibrosis (IPF) and other fibrosing ILDs.
Many ILDs are not only irreversible, but also progressive in nature [1]. The debilitating symptoms and the
knowledge of a poor prognosis heavily affects ILD patients’ physical, mental and emotional wellbeing [2].
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Antifibrotic therapies available in IPF were approved primarily because they slow down disease
progression, but have not so far been demonstrated to have a significant impact on patient wellbeing [3].
In parallel with the need to identify interventions that can preserve or improve patient quality of life [4],
there is a need to utilise and further develop objective measures of patients’ own perceptions of their
health-related quality of life (HRQoL) so they can be assessed appropriately [5]. A new PRO measure
(PROM), the Living with Idiopathic Pulmonary Fibrosis questionnaire (L-IPF) has suggested a beneficial
impact of antifibrotic treatment in non-IPF progressive fibrotic ILD [6]. Therefore, the use of such PROMs
to study the impact of existing and novel antifibrotic medications on HRQoL are needed [4].
A PRO is a self-reported health outcome directly reported by the patient who experiences it without
interpretation by an intermediary such as healthcare professionals, informal caregivers or their proxies, not
obtainable in any other manner and represents the patients’ perspective on their own symptoms, function,
psychological problems, health status and overall HRQoL. These measures are extremely important as they
provide a real understanding of the impact of disease and its treatments on health status from a patient’s
perspective. Objective outcome measures used in ILD clinics and research (for example, change in
pulmonary function) that are considered important by physicians do not necessarily align with patient
priorities. Qualitative studies suggest that the objective measures used in ILD clinics are viewed by patients
as disconnected from their experience of the disease [7]. Inclusion of PROs in such situations draws
clinical attention to what matters most to patients [8–11]. Thus, the use of PROs as research study
end-points and clinical follow-up tools may allow inclusion of patient narratives that have been largely
ignored by modern medicine [12]. PRO should be considered as complementary to traditional efficacy
measures and are not meant to replace them.
The overarching purpose of PRO inclusion in clinical research is to ensure that research conducted
eventually improves clinical care, patient experience and healthcare systems and is of high value to all
stakeholders, including patients and society. As a result, the development of relevant PROs and their use in
research and care has received encouragement from professional societies, regulatory bodies, health
systems and payers and patient advocacy groups [13].
PROMs are dedicated tools to assess PROs. They may be collected via self-administered questionnaires or
through patient interviews if the data obtained are reported directly. They are distinct from patient-reported
experience measures, which report on patient experience of care, settings and processes [14]. PROs should
not be confused with patient-centred outcomes that are directly relevant to patients, but may not be









Physiological,  imaging, biomarkers, 
hospitalisation, survival
Symptoms, i.e. dyspnoea, cough, fatigue 
HRQoL: patient feelings and perceptions of 
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Patient-centred outcomes
FIGURE 1: Comprehensive outcomes assessment in interstitial lung disease (ILD)/idiopathic pulmonary
fibrosis/progressive fibrotic ILD. HRQoL: health-related quality of life; PESaM: patient experience and
satisfaction with medication.
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PROMs can be generic, symptom- or disease-specific measures. Generic PROMs are designed for use in a
disease or general population sample and may exclude important aspects that are relevant to specific
diseases. Symptom-specific measures are dedicated tools used to assess specific symptoms such as
dyspnoea or cough. In contrast, condition-specific PROMs are designed to assess patient views across
various domains within a particular health condition or diagnostic group such as cancer or chronic illness
and are only suitable for use in that population. PROM use may improve patient satisfaction, clinician
satisfaction, efficiency and communication, and can support joint decision-making [16–19]. PROMs can
assist in monitoring symptoms, response to therapeutic interventions and serve as a screening tool for
physical and emotional problems that require additional clinical interventions [20–23]. While most patients
welcome their use in care, physicians often remain reluctant to use PROMs routinely because of lack of
confidence in their value and the time needed for implementation [24].
In December 2019, a working group of 63 international ILD experts assembled for the third time at the
Ettore Majorana Foundation and Centre for Scientific Culture in Erice, Italy, to discuss priority clinical and
research issues in ILD. Participants represented 17 countries in Europe and North America. Among the
topics of discussion during this 3-day meeting were the current PROMs for patients with IPF. In pro–con
debate and round-table discussion formats, it was discussed whether PROMs must be incorporated as
efficacy end-points in ILD clinical trials. Given the critical unmet need, the current experience and
challenges with PROMs, this review was prepared by the primary participants of discussion on this issue
(authors) and incorporating input from all other participants of the Erice ILD working group (collaborators)
to catalogue needs, gaps and possible future directions to facilitate understanding and research in PROMs
for ILD.
History of PROM use in ILD/IPF
Over the past decade, there has been an increasing recognition of the need to engage in patient-centred
research and to use PROMs in the process [25–28]. The growing awareness that care must be
comprehensive, holistic and benefit the whole person, and not just address disease pathobiology has
propelled multiple stakeholders across various sectors to embrace PROMs. This requires tools that can
measure concepts relevant to the wellbeing of the person as a whole and assess whether specific treatments
benefit these domains of health (figure 1). It is equally important to recognise when the interventions
could have a negative impact on HRQoL. Thus, traditional clinical research outcomes in ILD/IPF such as
pulmonary function, while important, are not sufficient or comprehensive enough from the patient’s
perspective, and outcomes that include a focus of patient and carer perceptions are needed [7]. The
assessment of how an intervention affects symptoms, function and HRQoL should be considered an
equally important research outcome; for example, “Can I go out for a walk without feeling too breathless?”
or “Could the side-effects of this therapy worsen my quality of life further?” instead of “Has my
spirometry or walk distance improved?” Such aspects of disease experience can only be ascertained by
asking patients directly or by using PROMs.
PROMs have been used for over a decade in IPF/ILD clinical drug trials, mostly as secondary end-points
(table 1). Unfortunately, most of the trials failed to demonstrate significant effect on HRQoL, despite a
benefit on lung function outcome for some interventions. This has multiple probably reasons, such as the
nature of interventions aiming to modify fibrosis by slowing down disease progression, the use of PROMs
not specifically developed for IPF/ILD, too short an observation time, inclusion of populations without
sufficiently severe disease, and their use in multinational settings with PROMs failing to take into account
the inherent sociocultural differences in expectation. PROMs have been used successfully used in
pulmonary rehabilitation trials in ILD/IPF [46]. These were not included in our discussion as it was
considered out of scope. A recent Cochrane systemic review of 21 such studies demonstrated meaningful
improvement in dyspnoea and HRQoL as measured by the Chronic Respiratory Disease Questionnaire
(CRQ) and the St George’s Respiratory Questionnaire (SGRQ) for participants with ILD and for the
subgroup of people with IPF.
Among the numerous available PROMs, SGRQ has been most frequently used; it was originally developed
for COPD and asthma [47–49]. Although validated in IPF, it may not provide assessment of all relevant
aspects of IPF/ILD [50]. Therefore, SGRQ was modified to create an IPF-specific version, SGRQ-I
(SGRQ-IPF), and validated in IPF [51]. Other generic measures such as EuroQol five dimensions
(EQ-5D), 36-item short form (SF-36) and University of California San Diego (UCSD) Shortness of Breath
Questionnaire have also been used in IPF (table 2). Several of these PROMs (EQ-5D, SF-36, COPD
Assessment Test) have been validated in the IPF population, resulting in confirmation of acceptable
measurement properties [11, 52, 78, 79]. Importantly, none of these instruments were developed
specifically for the ILD population and were created prior to release of PROM guidance documents from
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TABLE 1 Summary of patient-reported outcome measures (PROMs) in idiopathic pulmonary fibrosis (IPF)/interstitial lung disease (ILD)
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regulatory authorities such as the US Food and Drug Administration (FDA) [80] and the European
Medicines Agency (EMA) [81]. In light of the increasing importance of PROMs and their use in clinical
drug trials, these regulatory authorities created guidance documents to facilitate proper development,
validation, testing and use of these tools in research settings. The King’s Brief Interstitial Lung Disease
Questionnaire (K-BILD) is the first ILD-specific PROM that was developed explicitly for this
population [61]. It has been validated for use in IPF in subsequent studies [82]. This was a key step in the
right direction as demonstrated by its effective use in a recent clinical pharmacotherapeutic trial by VISCA
et al. [41]. In a randomised controlled trial (RCT) to assess the effect of ambulatory oxygen on quality of
life using PROMs as primary outcomes, clinically significant results were noted for the first time in an
ILD drug trial [41]. In contrast to previous studies, this trial used K-BILD, an ILD-specific PROM and
studied a treatment that directly targeted symptoms and quality of life. This suggests that the use of
disease-specific PROMs that are validated rigorously and chosen thoughtfully may be more efficacious and
may help move the field forward. L-IPF is a recently validated PROM developed specifically for IPF and
concordant with FDA guidance [66]. L-IPF assesses symptoms, disease impact and HRQoL, but it only
indirectly assesses mood [6]. In addition, it does not assess therapy-related effects that can adversely affect
HRQoL and longitudinal validity remains to be established. L-IPF was used as a secondary outcome
measure in INBUILD, an RCT investigating the effects of nintedanib on progressive fibrotic ILD and
showed significant results published as an abstract [6]. As more high-quality PROMs are developed and
tested using rigorous methodologies, we hope they will be increasingly used in clinical trials to assess the
impact of interventions on HRQoL.
PROM development
PROM development can be a long, arduous and costly process. Figure 2 describes the various steps in its
development as outlined by FDA draft guidance and the EMA reflective paper. The first step involves the
development of a preliminary instrument with a pool of items by creating a conceptual framework or
model, based on literature and expert review. The content pool undergoes further refinement with inclusion
of new items generated based on interviews with patients and further expert input. Item response theory
and Rasch measurement theory are the preferred methods for item development and testing [83]. Response
options, recall period and tool format are determined. The item bank then undergoes further refinement
and reduction, again based on interviews with patients. This is done through cognitive interviewing or
testing that involves “verbal probing” to determine the readability, acceptability of the format and structure
of the instrument, interpretation of items and formulation of response [84]. After cognitive testing with
patients, a pilot draft is further optimised to create the final instrument and subsequently tested. Once the
tool has been developed in this fashion, cross-sectional and longitudinal validation is performed (figure 2).
Thereafter, the questionnaires may be translated into various languages for wider use and undergo related
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No difference in worsening of HRQoL and
dyspnoea between the two arms
CRQ: Chronic Respiratory Disease Questionnaire; NS: nonsignificant; HRQoL: health-related quality of life; SGRQ: St George’s Respiratory
Questionnaire; SF-36: 36-item short form; MDI: Mahler Dyspnoea Index; NR: not reported; IFN: interferon; UCSD-SOBQ: University of San Diego
Shortness of Breath Questionnaire; EQ-5D: EuroQol five dimensions; TDI: Transitional Dyspnoea Index; ICE-CAP: Investigating Choice Experiences
Capability instrument; CASA-Q: Cough and Sputum Assessment Questionnaire; K-BILD: King’s Brief Interstitial Lung Disease Questionnaire; HADS:
Hospital Anxiety and Depression Score; LCQ: Leicester Cough Questionnaire; VAS: visual analogue scale.
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for varying patient perceptions governed by social and cultural conditions. For PROMs to be useful in
diverse, multicultural, multilingual populations of rare diseases and clinical trials, they must be adapted to
target populations.
Challenges of PROMs: development, validation and implementation
Problems in development
As noted earlier, PRO end-points mostly fail as (predominantly secondary) end-points in clinical trials
aimed at disease modification in IPF [85]. Table 2 reviews characteristics and measurement properties of
PROMs commonly used in ILD that can help inform the reasons behind this disappointing result. As
outlined, all PROMs except K-BILD and L-IPF were developed in non-ILD populations. The lack of
disease-specific rigorously developed tools has precluded confident use of PROMs in ILD research [85].
Furthermore, none of the symptom-specific PROMs, as listed in table 2, were originally developed for IPF
[70, 86–88]. Although cough is a common symptom of many ILDs, questionnaires have not been
developed to assess cough severity or its impacts specifically for patients with ILD [89]. The Leicester
Cough Questionnaire and the Cough Quality of Life Questionnaire, developed in patients with chronic
cough, are currently used in IPF-related cough [90, 91]. Similarly, there are no ILD-specific questionnaires
to assess fatigue, a common and debilitating symptom for many patients with ILD. However, the Fatigue
Assessment Scale, developed and validated in sarcoidosis, has been used in IPF [92, 93].
Another concern with PROMs is that they are likely to be more precise in capturing patient perceptions
and their variation over time in homogeneous target populations, such as patients within a set range of
disease severity [94]. This may limit their generalisability to large, multicentre and multinational clinical
trials with widespread geographic, cultural and socioeconomic differences between participating patient
populations [95]. Furthermore, if a wide range of disease severity is represented in a therapeutic trial, the
realistic patient goals, expectations and perceptions may further vary greatly. This is a well-known
challenge in many rare diseases with heterogeneous populations and variable disease courses. This was
Cross-sectional evaluation of the instrument
Does it work well?
Assessment of measurement properties
  Reliability
    internal consistency of the items
    reproducibility and measurement error by test–retest
  Construct and criterion validity
    ability to distinguish in hypothesised and known groups
    correlations with an assumed gold standard
    correlations with related measures




  Generate new items from patient and expert input
  Select recall period, response options, format and method
  Evaluation of face, content and structural validity:
    cognitive interviews with patients
    pilot test with dra" instrument
    selection of items
  Finalisation of the instrument
II
Preliminary instrument development
What, for whom, and how?
  Determine measurement aim (concepts), intended
  population and application
  Perform literature review/expert review
  Construct a framework of aimed concepts
  Construct a pool of items
I
Modification of the instrument
Does it work in di!erent settings?
In case of changes, new validation is needed
  Translation
  Cultural adaptation
  Mode/method of administration
  Response options




Longitudinal evaluation of the instrument
Does it capture changes?
  Assessment of responsiveness/ability to
  detect change
  Determine the MCID
IV
FIGURE 2: Development of patient-reported outcome measures (PROMs). MCID: minimal clinically important difference. Adapted from US Food and
Drink Administration guidance on the development of a PROM instrument for drug development to support labelling claims [80].
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observed in the INPULSIS trials, where a significant reduction in loss of HRQoL as measured by PROMs
(including SGRQ) was seen in the treatment group compared to placebo in patients with more severe IPF,
but not in those with less advanced disease, suggesting that the PROMs used may have a lower sensitivity
to change in patients with less severe IPF [96].
Other explanations for the low sensitivity of PROMs in ILD/IPF trials could be related to the confounding
effect of differences in language, practices and expectations between people from different countries and
cultures [97]. The importance of linguistic validation has increasingly been acknowledged with PROMs
intended for use in a heterogeneous population (see also later). All these issues may lead to limitations in
generalisability of PROMs.
Cross-sectional validity and reliability
The validity of PROMs can be assessed in a variety of ways, including the demonstration of
moderate-to-high correlation with existing measures that address the same concept (convergent validity),
low correlation with measures that assess other concepts (divergent validity) and responsiveness to
meaningful change. Reliability refers to the consistency of a measure. The main types of consistency are
over time (test–retest reliability) and across items (internal consistency) [98–100]. Internal consistency
determines the consistency of responses from an individual across the items on a multiple-item measure [100].
The FDA guidance emphasised test–retest reliability as the most important reliability type, while internal
consistency may be used in the absence of information on the test–retest reliability [100].
Evaluating the measurement properties of PROMs in rare diseases can be challenging because of the small
number of patients in addition to heterogeneous populations. For example, the COPD-specific SGRQ, used
to assess HRQoL in IPF [47], is self-reported, and has 50 items split into three domains: “symptoms”,
“activity” and “impacts” [101]. Validation in IPF [50] concluded that the internal consistency of the
activity and impacts domains and the total score from the SGRQ was excellent, whereas the consistency of
the symptoms domain was moderate, probably due to different symptom characteristics (e.g. wheeze and
sputum production are not common in patients with IPF/ILD). An important point to note is that for most
PROMs, as part of validation, the PROM data are usually compared to other quality-of-life tools and lung
function data. Comparing newer ILD tools to SGRQ, not specific to IPF, in whole or single domains is
less than ideal. In the same way, many HRQoL and dyspnoea PROMs are validated against lung function
data or other tools that in turn use lung function for validation. However, a study by GRØNSETH et al. [102]
showed that only 13% of dyspnoea variance can be explained by the usual confounders, including lung
function, suggesting that they are not ideal comparators for validation. In addition, their study highlighted
significant variation in dyspnoea prevalence across 15 countries, probably associated with differences in
patient perception of symptoms. Therefore, these data call into question the cross-cultural validity of many
such instruments, not just limited to dyspnoea scales, but also the HRQoL tools that include dyspnoea as
part of their domains [102]. K-BILD, although an ILD-specific PROM, has an important limitation in the
lack of some health issues relevant to ILD, such as cough, that are not included in the final version of the
K-BILD [61]. The process of development, testing and validation of K-BILD was concordant with FDA
indications, but unfortunately led to the exclusion of cough by the Rasch theory [80]. This highlights the
particular challenge of including a large heterogeneous derivative cohort to cover all relevant aspects of
disease that can vary across severity.
Longitudinal responsiveness
Longitudinal studies are performed to ensure reliability (stable and consistent results), reproducibility (to
obtain similar results under similar conditions) and responsiveness of PROMs (the ability to detect changes
over time). Such robust psychometric properties are a pre-condition for PROM use and tools are generally
considered valid if supported by this type of statistical evidence. For research use, PROMs must not only
be valid and reliable, but also have minimal clinically important difference (MCID) determination,
i.e. measure the smallest change in outcome that an individual patient would identify as important. Access
to validated MCIDs for PROMs in ILD/IPF will facilitate understanding of the clinical relevance and
magnitude of the effect of a specific intervention from a patient’s perspective, allow sample size
calculations and help define expected end-points in clinical trials [103]. In addition, the context of MCID
use and interpretation is an important factor to consider. For example, a recent study by PRIOR et al. [55]
suggested that the MCID for determining improvement in HRQoL may be different from that for
worsening as detected by both SGRQ-I and K-BILD in IPF. MCID for improvement differed from
deterioration for both SGRQ-I total score (3.9 and 4.9, respectively) and K-BILD total score (4.7 and 2.7,
respectively). The MCID of an instrument in different disease stages may be variable. In IPF, quality of
life seems to worsen abruptly in the last years before death [104], and it may therefore be that PROMs
have divergent outcomes in more advanced disease stages compared to early disease.
https://doi.org/10.1183/16000617.0026-2021 9
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Cultural differences, differing expectations and language issues may also influence MCID. A systematic
review suggested that a wide range of MCID values may exist for the same questionnaire and the
difference between significance and clinical importance needs to be clarified. Therefore, MCID determined
in one cohort of IPF patients may not be applicable to multicentre trials that enrol participants with
wide-ranging sociocultural backgrounds with varying understanding of health and disease and related
expectations. Consensus is needed for appropriate usage of MCID-determining equations [105]. Typically,
a combination of anchor- and distribution-based methods are applied in this process, where current health
status and change over time from a patient’s point of view are used as anchors.
Specifically considering PROM measurement in ILD/IPF, longitudinal responsiveness was documented for
some of the most used PROMs, including SGRQ, SGRQ-I and K-BILD [51, 62, 82]. However, a growing
interest in PRO research in IPF has generated limited data that also support the validity of the baseline
dyspnoea index/transition dyspnoea index, UCSD Shortness of Breath Questionnaire, SGRQ, SF-36,
five-level EQ-5D and EQ-VAS [57] for use as longitudinal outcomes in IPF trials [25].
Sociocultural diversity in the different cohorts engaged in development and testing of PROMs are
necessary to ensure required adaptations, appropriate sensitivity and accuracy in reflecting patient
perceptions. For a PROM to be usable, it should embrace the intended patient population. For example,
symptoms perceived as side-effects in Western cultures (for instance diarrhoea due to antifibrotic
treatment) may in other cultures be seen as a desirable elimination of disease-related “badness”. Thus,
PROMs should be validated with respect to cultural background in addition to the usual psychometric
properties.
PROM burden of use
The administrative burden of responding to PRO questionnaires, their collection, storage, interpretation and use is
another relevant issue. The length of the questionnaire may impose a challenge even for the healthier patients;
sicker patients with advanced disease might find that responding to PRO questionnaires is even more
burdensome [106]. Potential factors related to response burden include the length and/or formatting of the
questionnaire or interview, issues with literacy level and issues related to the mode of administration (e.g. paper-,
telephone- or web-based surveys). In addition, there may be issues related to sensitive content of items that
participants may be unwilling to answer, or patients’ perception that an interviewer expects a specific response.
Many of the available IPF/ILD questionnaires are not practical for clinical use, mainly due to the time
taken to complete the questionnaires. Time is the main barrier reported by clinicians to implementing
questionnaires in their routine care, probably because many PROMs are extensive and mostly developed
for research use [107]; shorter and more reliable measures can improve response rates [24]. However,
longer questionnaires provide more possibilities to capture all aspects that are deemed important for an
adequate evaluation of several aspects of the disease. There is an urgent need to make PROMs more
efficient to aid implementation and compliance while maintaining its integrity. The use of computerised
adaptive testing offers a potential solution by decreasing the question burden on the patients [108]. Data
science tells us that the scores of PROMs can be accurately predicted from fewer questions if the correct
questions are asked [109]. Computerised adaptive testing aims to identify the subset of questions from the
full instrument to ask each patient based on his/her previous responses. This can reduce patient burden
without compromising the precision of measuring their perceptions [110]. Therefore, computerised
adaptive testing methodology for disease-specific PROMs must be studied in ILD. Striking the right
balance between comprehensiveness, utility and length is challenging and may be tailored towards different
aims, i.e. research or clinical practice. This requires frequent monitoring and reassessment of processes.
Finally, successful implementation of PROMs requires support for healthcare practitioners and substantial
resource investment for training the staff that could make practical data collection challenging.
Recommendations
PROMs are increasingly emphasised in ILD as we transition from disease-centred to patient-centred, and
from volume-based to value-based healthcare. Patient-focused drug development also requires increasing
use of PROMs. In the case of IPF/ILD, where a patient’s quality of life is significantly impaired to begin
with, assessments of any intervention must include patient perspectives on overall impact on function,
symptoms and quality of life in addition to impact on traditional biomedical outcomes. PROMs must be
measured and reported in trials, even if the interventions are not expected to improve PROs, to ensure that
patient perspectives on tolerability, impact and burden of therapy are fully assessed. The use of such
measures will allow clinicians and researchers alike to understand the total impact of disease and therapy on
PROs and shed light on issues of tolerability and acceptability of therapy, which cannot be discerned
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otherwise. Given the number of therapeutic agents in development with varying targets and probable diverse
adverse effects that can negatively affect HRQoL, such measures should be included in clinical drug trials.
We highlight needs and recommendations for PROM use in IPF/ILD in table 3. The quality of a PROM
and its ability to provide dependable results is essential for its meaningful use. ILD-specific PROMs
should be prioritised and validated in both cross-sectional and longitudinal settings where different
measurement properties are studied. The development and validation of instruments such as K-BILD,
SGRQ-I and L-IPF will help move the field forward, and wherever possible, efforts should be made to use
ILD-specific PROMs over PROMS such as SGRQ that were originally developed for other diseases.
Validation can be perceived as an iterative process and should serve to improve the robustness and
generalisability by assessing the PROM instruments in different populations, cultures and disease settings.
In addition to robust psychometric properties, we need culturally sensitive, specific PROM tools responsive
to varying disease severity, including end of life. Varying cultural, social and psychological factors
influence patient perceptions; hence, what is meaningful and expected in one geographical area may differ
significantly from another, underlining the need for testing across different populations. Cultural adaptation
is often overlooked when developing and translating PROMs and this can have significant impact on
quality of data, including attrition and missing data. There are many recommendations for adapting
PROMs to ensure equivalence and validity across various cultural groups [111]. Pooling of data from
international studies to assess cultural validity of psychometric properties of a PROM or to establish
suitable MCIDs can be considered. Determination of MCID for both improvement and deterioration is
desirable for appropriate interpretations and reporting of patients’ HRQoL.
When deciding on PROM use in a clinical trial, the concept of interest measured by the PROMs should
meet the aim of the research study. For example, in ILD drug trials, the investigators may want to
comprehensively assess impact of intervention on all domains relevant to patients in addition to measuring
traditional biomedical markers. This necessitates the use of PROMs that are disease-specific and validated
HRQoL instruments (e.g. K-BILD, L-IPF) instead of using instruments such as SGRQ that were developed
primarily for COPD populations. Another concept of interest can be patient self-efficacy; CRQ may be a
good choice in this case, as it measures mastery of symptom control as a domain. Similarly, Dyspnoea-12
can be helpful to assess physical and affective responses to breathlessness without depending on activity
levels, which are the focus in many dyspnoea instruments. Recall periods of PROMs are variable, and this
should be kept in mind when choosing instruments. PROM use in drug trials poses another challenge. All
drug interventions are likely to cause adverse effects with varying impacts on HRQoL; these may not be
captured by the disease-specific PROMs and additional instruments may be needed to assess impact of
these adverse effects. For example, diarrhoea or skin rash, which as adverse effects can impair HRQoL, are
not measured by ILD/IPF-specific HRQoL instruments, but can be meaningfully reported from the patient
perspective. Specific PROMs to capture adverse effects, such as the Patient-Reported Outcomes version of
the Common Terminology Criteria for Adverse Events [112], were developed and tested for use in cancer
TABLE 3 Urgent needs and recommendations for patient-reported outcome measures (PROMs) in idiopathic
pulmonary fibrosis/interstitial lung disease (ILD)
Recommendations
Choice of PROM ILD-specific PROMs should be prioritised
The concept of interest in the PROM should meet the aim of the clinical trial
PROMs should be selected according to the population of interest
PROMs to measure impact of adverse effect/harm from drug interventions
Measure patient experience of therapy burden
Development based on IRT or Rasch measurement theory
PROM validation Language validation
Cultural validation
Cross-sectional and longitudinal validation (MCID)
MCID determination for improvement and deterioration
Operability PROMs should be simple and short
PROMs should be linguistically adapted to the population of interest
PROM could utilise computerised adaptive testing
Collection of data in real time Use a device/device of patients’ choice
Use new technology, including audio and touch screen options
IRT: item response theory; MCID: minimal clinically important difference.
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drug trials. Such tools can help assess impact/harm of cancer therapies as PROs. Similar tools for ILD/IPF
are needed. Reporting of adverse effect frequency, severity and distribution alone is not enough, but the
degree of interference with HRQoL should also be considered. The need for measurement of both harm
and benefit from the patient perspective should be considered when selecting PROMs in drug trials. The
burden of therapy may need to be measured if the administration is complex (parenteral route or number of
pills, etc.). Instruments such as patient experience and satisfaction with medication and other
patient-reported experience measures may be useful in this regard. The selection of PROMs that measure
symptoms of interest such as dyspnoea, cough or fatigue may also be considered, as they are more relevant
to patients and it is important to document positive or negative impact of interventions on symptoms. It
should be selected according to the population of interest (e.g. early versus advanced disease) and be
available in several languages, with cultural validity as described earlier. Results of PROM may vary in
different populations. For instance, patients in clinical trials are highly selected and differences between
trial and non-trial populations may very well exist. This must be acknowledged in the interpretation of
results. A PROM should consider whether the population is initiating treatment, on treatment or living with
or beyond the disease [113]. In addition, appropriate selection requires that users are familiar with PROMs,
their properties, MCID, attendant limitations and the need for contextual interpretation. Researchers must
select the appropriate MCID for the PROM of interest, as the unit change for improvement and
deterioration may be different. One way to improve PROMs is to involve patients more, not only as
consultants, but also as active partners in the development and implementation of PROMs. Patient
involvement can optimise the relevance of a PROM and support patient-centred research and care [114].
Patients can advise on using acceptable language to make the completion of an instrument easier, and to
ensure that it is not burdensome for well or unwell patients [113]. To improve the integration of the patient
voice throughout the development, implementation and dissemination of a PROM, patients need to be part
of the process from the beginning [115]. By including patients from the outset, this can enable a truly
collaborative approach with patients, patient advocates and, in some instances, caregivers [115, 116].
PROMs should be practically feasible and operational, and easy to implement for patients and the
healthcare staff administering them. New digital tools enable patients to complete questionnaires online
with direct data transmission either from home or at the clinic, reducing some of the burden. Use of digital
platforms can ensure consistent administration, storage and interpretation of data. The imposed response
burden on patients and healthcare providers must be carefully weighed against the clinical and research
need for comprehensive tools. PROMs with the minimum possible number of items that can provide a
broad assessment of relevant domains are needed to reduce this burden. With increasing confidence in
well-developed PROM tools and their greater use in clinical studies, we can look forward to exciting times
in medicine where patients and their perceptions are truly at the centre of care and research.
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